Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opiant Pharmaceuticals
Pharma
Indivior grounds schizophrenia drug, triggering 130 layoffs
Indivior has slashed its projected revenue increase for 2024 from 18% to 8%, citing competitive pressure for top-selling product Sublocade.
Kevin Dunleavy
Jul 10, 2024 11:39am
Indivior's overdose rescue spray Opvee crosses FDA finish line
May 23, 2023 2:42pm
FDA moves to boost access to overdose reversal med
Nov 16, 2022 7:15am
Indivior inks $145M Opiant buyout for nasal opioid overdose drug
Nov 15, 2022 9:25am
BARDA backs Opiant to get overdose drug over the FDA line
Aug 9, 2022 10:28am
Opiant races to FDA after nasal overdose drug matches Narcan
May 3, 2022 9:35am
